SECUKINUMAB IN GIANT CELL ARTERITIS: THE RANDOMISED, PARALLEL-GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTRE PHASE 2 TITAIN TRIAL

被引:6
|
作者
Venhoff, N. [1 ]
Schmidt, W. A. [2 ]
Bergner, R. [3 ]
Rech, J. [4 ]
Unger, L. [5 ]
Tony, H. P. [6 ]
Mendelson, M. [7 ]
Sieder, C. [8 ]
Maricos, M. [8 ]
Thiel, J. [1 ,9 ]
机构
[1] Univ Freiburg, Vasculitis Ctr Freiburg, Dept Rheumatol & Clin Immunol, Med Ctr, Freiburg, Germany
[2] Med Ctr Rheumatol Berlin Buch, Immanuel Krankenhaus Berlin, Berlin, Germany
[3] Klinikum Stadt Ludwigshafen, Med Klin, Ludwigshafen, Germany
[4] Friedrich Alexander Univ FAU Erlangen Nurnberg, Dept Internal Med Rheumatol & Immunol 3, Erlangen, Germany
[5] Stadt Klinikum Dresden, Med Dept 1, Dresden, Germany
[6] Rheumatol & Clin Immunol Oberduerrbachertstr, Dept Med 2, Wurzburg, Germany
[7] Novartis Pharmaceut, Rheumatol, Newark, NJ USA
[8] Novartis Pharma GmbH, Rheumatol, Nurnberg, Germany
[9] Med Univ Graz, Div Rheumatol & Immunol, Dept Internal Med, Graz, Austria
关键词
D O I
10.1136/annrheumdis-2022-eular.806
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OP0182
引用
收藏
页码:121 / 122
页数:2
相关论文
共 50 条
  • [21] The efficacy and safety of 'antianxiety granule' for anxiety disorder: a multicentre, randomized, double-blind, placebo-controlled, parallel-group trial
    Zhongwei Sha
    Yiping Hou
    Chunchun Xue
    Ou Li
    Zhimin Li
    Huiru Wang
    Wenjing Zhang
    Jian Xu
    Trials, 21
  • [22] Letter: budesonide for functional dyspepsia with duodenal eosinophilia-randomised, double-blind, placebo-controlled parallel-group trial
    Talley, N. J.
    Walker, M. M.
    Jones, M.
    Keely, S.
    Koloski, N.
    Cameron, R.
    Fairlie, T.
    Burns, G.
    Shah, A.
    Hansen, T.
    Harris, G.
    Holtmann, G.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2021, 53 (12) : 1332 - 1333
  • [23] Varenicline and counseling for vaping cessation: a double-blind, randomized, parallel-group, placebo-controlled trial
    Pasquale Caponnetto
    Davide Campagna
    Jasjit S. Ahluwalia
    Christopher Russell
    Marilena Maglia
    Paolo Marco Riela
    Carmelo Fabio Longo
    Barbara Busa
    Riccardo Polosa
    BMC Medicine, 21
  • [24] Varenicline and counseling for vaping cessation: a double-blind, randomized, parallel-group, placebo-controlled trial
    Caponnetto, Pasquale
    Campagna, Davide
    Ahluwalia, Jasjit S.
    Russell, Christopher
    Maglia, Marilena
    Riela, Paolo Marco
    Longo, Carmelo Fabio
    Busa, Barbara
    Polosa, Riccardo
    BMC MEDICINE, 2023, 21 (01)
  • [25] Dipeptidyl peptidase-1 inhibition in patients hospitalised with COVID-19: a multicentre, double-blind, randomised, parallel-group, placebo-controlled trial
    Keir, Holly R.
    Long, Merete B.
    Abo-Leyah, Hani
    Giam, Yan Hui
    Vadiveloo, Thenmalar
    Pembridge, Thomas
    Hull, Rebecca C.
    Delgado, Lilia
    Band, Margaret
    McLaren-Neil, Fiona
    Adamson, Simon
    Lahnsteiner, Eva
    Gilmour, Amy
    Hughes, Chloe
    New, Benjamin Jm
    Connell, David
    Dowey, Rebecca
    Turton, Helena
    Richardson, Hollian
    Cassidy, Diane
    Cooper, Jamie
    Suntharalingam, Jay
    Diwakar, Lavanya
    Russell, Peter
    Underwood, Jonathan
    Hicks, Alexander
    Dosanjh, Davinder Ps
    Sage, Beth
    Dhasmana, Devesh
    Spears, Mark
    Thompson, Aa Roger
    Brightling, Christopher
    Smith, Andrew
    Patel, Manish
    George, Jacob
    Condliffe, Alison M.
    Shoemark, Amelia
    MacLennan, Graeme
    Chalmers, James D.
    LANCET RESPIRATORY MEDICINE, 2022, 10 (12): : 1119 - 1128
  • [26] An innovative combination of cypropheptadine and prazosin for the treatment of alcohol use disorder: a double-blind, randomised, parallel-group, three-arm, multicentre, placebo-controlled phase 2 trial.
    Aubin, H. -J.
    Puech, A.
    EUROPEAN PSYCHIATRY, 2022, 65 : S126 - S126
  • [27] Efficacy and safety of suvratoxumab for prevention of Staphylococcus aureus ventilator-associated pneumonia (SAATELLITE): a multicentre, randomised, double-blind, placebo-controlled, parallel-group, phase 2 pilot trial
    Francois, Bruno
    Jafri, Hasan S.
    Chastre, Jean
    Sanchez-Garcia, Miguel
    Eggimann, Philippe
    Dequin, Pierre-Francois
    Huberlant, Vincent
    Soria, Lucia Vina
    Boulain, Thierry
    Bretonniere, Cedric
    Pugin, Jerome
    Trenado, Josep
    Padilla, Ana Catalina Hernandez
    Ali, Omar
    Shoemaker, Kathryn
    Ren, Pin
    Coenjaerts, Frank E.
    Ruzin, Alexey
    Barraud, Olivier
    Timbermont, Leen
    Lammens, Christine
    Pierre, Vadryn
    Wu, Yuling
    Vignaud, Julie
    Colbert, Susan
    Bellamy, Terramika
    Esser, Mark T.
    Dubovsky, Filip
    Bonten, Marc J.
    Goossens, Herman
    Laterre, Pierre-Francois
    LANCET INFECTIOUS DISEASES, 2021, 21 (09): : 1313 - 1323
  • [28] Erythromycin for myotonic dystrophy type 1: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
    Nakamori, Masayuki
    Nakatani, Daisaku
    Sato, Tomoharu
    Hasuike, Yuhei
    Kon, Seiko
    Saito, Toshio
    Nakamura, Harumasa
    Takahashi, Masanori P.
    Hida, Eisuke
    Komaki, Hirofumi
    Matsumura, Tsuyoshi
    Takada, Hiroto
    Mochizuki, Hideki
    ECLINICALMEDICINE, 2024, 67
  • [29] Ginkgo biloba for mild to moderate dementia in a community setting: a pragmatic, randomised, parallel-group, double-blind, placebo-controlled trial
    McCarney, Rob
    Fisher, Peter
    Iliffe, Steve
    van Haselen, Robbert
    Griffin, Mark
    van der Meulen, Jan
    Warner, James
    INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, 2008, 23 (12) : 1222 - 1230
  • [30] Quetiapine or haloperidol as monotherapy for bipolar mania - a 12-week, double-blind, randomised, parallel-group, placebo-controlled trial
    McIntyre, RS
    Brecher, M
    Paulsson, B
    Huizar, K
    Mullen, J
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2005, 15 (05) : 573 - 585